株式会社極東書店トップ商品一覧Growth Hormone II: Basic and Clinical Aspects. Softcover reprint of the original 1st ed. 1994

商品詳細

Growth Hormone II: Basic and Clinical Aspects. Softcover reprint of the original 1st ed. 1994

Growth Hormone II: Basic and Clinical Aspects. Softcover reprint of the original 1st ed. 1994

・ISBN 978-1-4613-8374-1 paper EUR 99.99

¥26,726.- (税込) (※)価格はご注文時の参考価格となります。
納品価格につきましては書籍の入荷時点で確定となります。
版元の原価改定、外国為替の変動等により異なる場合がございますので、予めご了承下さい。

お気に入り
著者・編者Bercu, Barry B. / Walker, Richard F. (eds.),
シリーズ (Serono Symposia USA)
出版社 (Springer-Verlag New York Inc., US)
出版年月2011
ページ数379 pp.
言語ENG
ニュース番号<A04-84833>

解説

This book is a compendium of proceedings from the Symposium on Growth Hormone II: Basic and Clinical Aspects. The intent of the sym- posium was to review current aspects of the rapidly expanding science of growth hormone (GH) neuroendocrinology, especially those develop- ments that occurred since our last meeting in 1985. The meeting was timely since there have been many new and exciting developments in basic research on the GH axis, and several new clinical applications for GH other than growth have been identified. For example, significant strides have been made into use of the bioengineered hormone as an anabolic in debilitated states and as an immunorestorative agent. Both these areas have received most attention as they relate to geriatric popu- lations. Furthermore, recent focus on a novel family of GH secretagogues that complement the action of GHRH has shown that in animal models, these compounds have the potential to restore GH secretion in deficient or insufficient states, including growth retardation, obesity, and aging. Accordingly, these xenobiotics may have significant potential as drug products to stimulate physiological GH secretion and, thus, resist or reverse some of the maladaptive changes in form and function resulting from GH insufficiency. The importance of these agents as drug candidates is underscored by the diversity of molecules that have been studied by various pharmaceutical companies and the recent discovery that non- peptide analogs with high oral bioavailability can be synthesized.